FOLH1 and brain cancer: In this prospective clinical (proof-of-concept) study we assess the feasibility, safety, and (quantified) benefit of ssIA compared to IV administration of a PSMA-based radioligand in patients with malignant brain tumours with the aim to improve the potential of future PSMA-based RLT strategies.